Please login to the form below

Not currently logged in
Email:
Password:

PD-L1

This page shows the latest PD-L1 news and features for those working in and with pharma, biotech and healthcare.

Immutep spikes on trial of its LAG-3 drug with Keytruda

Immutep spikes on trial of its LAG-3 drug with Keytruda

The PD-1/PD-L1 checkpoint inhibitors that hit the market in 2015 have already transformed the standard of care for some cancers, but there is still a sizeable patient population ... so “the results showing an almost 50% [response] across all patients

Latest news

More from news
Approximately 15 fully matching, plus 255 partially matching documents found.

Latest Intelligence

  • Encouraging signs in biomarker R&D Encouraging signs in biomarker R&D

    The presence of PD-L1 expression is often associated with a better response to anti-PD-(L) 1 therapy. ... The confounding issue is that, in the case of PD-1/PD-L1 drugs, each developer uses its own companion diagnostic that is required to prescribe the

  • Immuno-oncology in 2019: the rapid evolution continues Immuno-oncology in 2019: the rapid evolution continues

    cells to identify and fight cancer: the PD-1 and PD-L1 checkpoint inhibitor immunotherapies. ... PD-1/PD-L1 inhibitors: Keytruda is King, but the market is developing fast.

  • AstraZeneca’s oncology renaissance AstraZeneca’s oncology renaissance

    olaparib) plus biologic PD-L1 immunotherapy Imfinzi (durvalumab). ... patients with higher levels of PD-L1 expression in their tumours.

  • Combined immunotherapies – potential and pitfalls Combined immunotherapies – potential and pitfalls

    We hope to capitalise further on the effects of single agent anti-PD-1/PD-L1 and anti-CTLA-4 monotherapy trials and see even greater survival benefits for patients.”. ... There are a variety of strategies attempting to overcome intrinsic resistance to

  • The good, the bad and the ugly The good, the bad and the ugly

    Companies are looking to pair their PD-1/PD-L1 checkpoint inhibitors with a variety of other agents to stimulate a more robust anticancer immune response,” says Xuan.

More from intelligence
Approximately 0 fully matching, plus 15 partially matching documents found.

Latest appointments

  • F-star hires ex-BMS immuno-oncology leader

    Hewill oversee the clinical development of F-star’s lead product candidate, FS118, a LAG-3/PD-L1-targeting tetravalent bispecific antibody currently in aphase 1 clinical trial, recruiting the  expansion

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Say Communications

Influencing positive behaviours and delivering change is what drives us, using thought leadership, education, social and professional engagement and compelling,...

Latest intelligence

Ludovic Helfgott
Novo Nordisk awakens its ‘Sleeping Beauty’
Biopharm emerges from troubled times to hit ‘solid growth’, says executive vice president Ludovic Helfgott...
How will the Tories’ historic win shape the NHS?
Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore the impact of December’s General Election result on 2020 and beyond...
CSR 'Christmas Spirit' 2019
OPEN Health champions CSR over Christmas by giving back to the community and increasing our activities and efforts...

Infographics